Regarding the effects of lipid-lowering agents on HDL kinetics and functions, rosuvastatin corrects HDL-apoA-I kinetics abnormalities, with an effect on both hypercatabolism and increased production rate in T2DM patients [39] and in non-diabetic patients with MetS [200]. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.